Mononeuropathy
diseaseOn this page
Summary
Mononeuropathy (MONDO:0001397) is a disease (an umbrella term covering 7 Mondo subtypes) with 29 GWAS associations across 13 studies and 4 clinical trials. Top therapeutic interventions include fulranumab. A subtype of peripheral neuropathy — broader associated-gene and molecular evidence is on the parent page (see Disease family below).
At a glance
- Umbrella term: 7 Mondo subtypes
- GWAS associations: 29
- Clinical trials: 4
Clinical features
No curated clinical features (Orphanet) for this disease.
Identifiers
Disease identifiers
| Field | Value |
|---|---|
| Canonical name | mononeuropathy |
| Mondo ID | MONDO:0001397 |
| EFO | EFO:0009558 |
| MeSH | D020422 |
| DOID | DOID:1188 |
| ICD-11 | 1866592137 |
| SNOMED CT | 128189008 |
| UMLS | C0494491 |
| MedGen | 99214 |
| Is cancer (heuristic) | no |
Data availability: 29 GWAS associations (13 studies).
Disease family
This is a subtype of peripheral neuropathy. Genetic, therapeutic, and trial evidence is largely curated at the broader-term level — see the parent page for the associated-gene cohort and molecular evidence.
Classification path: disease › human disease › disease by body system or component › nervous system disorder › peripheral nervous system disorder › peripheral neuropathy › mononeuropathy
Related subtypes (29): autoimmune neuropathy, autonomic neuropathy, ischemic neuropathy, polyneuropathy, neuritis, motor peripheral neuropathy, sensory peripheral neuropathy, uremic neuropathy, nerve compression syndrome, axonal neuropathy, diabetic neuropathy, acquired peripheral neuropathy, hereditary peripheral neuropathy, neuralgia, peripheral nerve lesion, nerve plexus disorder, traumatic neuropathy, radiation-induced neuropathy, vasculitic neuropathy, chronic idiopathic neuropathy, chemotherapy-induced neuropathy, infectious neuropathy, vitamin deficiency related neuropathy, paraproteinemia-associated neuropathy, neuropathy in cryoglobulinemia, neuropathy in endocrine disorder, sarcoid neuropathy, neuropathy, small fiber, idiopathic small fibers neuropathy
Subtypes (7): radial neuropathy, mononeuritis simplex, peroneal neuropathy, femoral neuropathy, sciatic neuropathy, tibial neuropathy, ulnar neuropathy
Genetics & variants
GWAS landscape
29 GWAS associations across 13 studies. Top hits map to 0 distinct genes (as reported by GWAS).
Top associations by p-value
| rsID | p-value | Gene | Risk allele | Odds ratio |
|---|---|---|---|---|
| chr2:217281820 | 1e-17 | A | 0.09 | |
| chr4:13195893 | 5e-16 | T | 0.11 | |
| chr19:8605262 | 1e-15 | T | 0.19 | |
| chr2:55869757 | 1e-15 | G | 0.09 | |
| chr2:59921805 | 8e-15 | G | 0.07 | |
| chr9:126899277 | 3e-12 | TA | 0.07 | |
| chr3:124756354 | 5e-12 | G | 0.09 | |
| chr4:8323653 | 1e-11 | C | 0.07 | |
| chr9:92514124 | 1e-11 | C | 0.07 | |
| chr14:94378610 | 1e-10 | T | 0.23 | |
| chr15:100152748 | 3e-10 | A | 0.09 | |
| chr16:53765367 | 4e-10 | T | 0.06 | |
| chr2:176028818 | 4e-10 | T | 0.07 | |
| chr2:33180615 | 2e-09 | G | 0.06 | |
| chr9:133565497 | 2e-09 | A | 0.08 | |
| chr1:149946719 | 2e-09 | G | 0.07 | |
| chr10:98240797 | 3e-09 | ATT | 0.06 | |
| chr1:102766961 | 5e-09 | G | 0.06 | |
| chr1:22064084 | 1e-08 | C | 0.06 | |
| chr15:66742474 | 1e-08 | A | 0.06 | |
| chr10:119663324 | 2e-08 | C | 0.06 | |
| chr10:27589391 | 2e-08 | T | 0.07 | |
| chr5:83519339 | 2e-08 | G | 0.13 | |
| chr3:136157283 | 2e-08 | G | 0.06 | |
| chr10:21510797 | 3e-08 | C | 0.05 | |
| chr6:85086735 | 3e-08 | CA | 0.08 | |
| chr7:44129973 | 3e-08 | C | 0.06 | |
| chr5:73343274 | 4e-08 | C | 2.21 | |
| chr1:68484837 | 5e-08 | A | 2.34 |
Top studies (by case count)
| Study | Lead author | Year | Cases | Controls | Title |
|---|---|---|---|---|---|
| GCST90473344 | UK Biobank Whole-Genome Sequencing Consortium | 2025 | 24,005 | 434,435 | Whole-genome sequencing of 490,640 UK Biobank participants. |
| GCST90667898 | UK Biobank Whole-Genome Sequencing Consortium | 2025 | 24,005 | 434,435 | Whole-genome sequencing of 490,640 UK Biobank participants. |
| GCST90079846 | Backman JD | 2021 | 13,929 | 368,599 | Exome sequencing and analysis of 454,787 UK Biobank participants. |
| GCST90083832 | Backman JD | 2021 | 13,929 | 368,599 | Exome sequencing and analysis of 454,787 UK Biobank participants. |
| GCST90473346 | UK Biobank Whole-Genome Sequencing Consortium | 2025 | 5,054 | 453,386 | Whole-genome sequencing of 490,640 UK Biobank participants. |
| GCST90473347 | UK Biobank Whole-Genome Sequencing Consortium | 2025 | 2,721 | 455,719 | Whole-genome sequencing of 490,640 UK Biobank participants. |
| GCST90726796 | Kim HI | 2026 | 2,705 | 41,321 | Exome sequencing and analysis of 44,028 British South Asians enriched for high autozygosity. |
| GCST90079848 | Backman JD | 2021 | 2,301 | 383,611 | Exome sequencing and analysis of 454,787 UK Biobank participants. |
| GCST90083834 | Backman JD | 2021 | 2,301 | 383,611 | Exome sequencing and analysis of 454,787 UK Biobank participants. |
| GCST90473345 | UK Biobank Whole-Genome Sequencing Consortium | 2025 | 482 | 9,131 | Whole-genome sequencing of 490,640 UK Biobank participants. |
Variant details and genetic-evidence tiers
Tier distribution (top 50 variants)
| Tier | Variants |
|---|---|
| Tier 1: coding | 0 |
| Tier 2: splice/UTR | 0 |
| Tier 3: regulatory | 0 |
| Tier 4: intronic/intergenic | 29 |
MAF distribution
| Bucket | Variants |
|---|---|
| common (>=0.05) | 0 |
| low_freq (0.01-0.05) | 0 |
| rare (<0.01) | 0 |
| unknown | 29 |
Functional consequences
| Consequence | Count |
|---|---|
| unknown | 29 |
Top variants
| rsID | Chr | Pos | Alleles | MAF | Consequence | Gene | p-value | Tier |
|---|---|---|---|---|---|---|---|---|
| chr2:217281820 | 1e-17 | Tier 4: intronic/intergenic | ||||||
| chr4:13195893 | 5e-16 | Tier 4: intronic/intergenic | ||||||
| chr19:8605262 | 1e-15 | Tier 4: intronic/intergenic | ||||||
| chr2:55869757 | 1e-15 | Tier 4: intronic/intergenic | ||||||
| chr2:59921805 | 8e-15 | Tier 4: intronic/intergenic | ||||||
| chr9:126899277 | 3e-12 | Tier 4: intronic/intergenic | ||||||
| chr3:124756354 | 5e-12 | Tier 4: intronic/intergenic | ||||||
| chr4:8323653 | 1e-11 | Tier 4: intronic/intergenic | ||||||
| chr9:92514124 | 1e-11 | Tier 4: intronic/intergenic | ||||||
| chr14:94378610 | 1e-10 | Tier 4: intronic/intergenic | ||||||
| chr15:100152748 | 3e-10 | Tier 4: intronic/intergenic | ||||||
| chr16:53765367 | 4e-10 | Tier 4: intronic/intergenic | ||||||
| chr2:176028818 | 4e-10 | Tier 4: intronic/intergenic | ||||||
| chr2:33180615 | 2e-09 | Tier 4: intronic/intergenic | ||||||
| chr9:133565497 | 2e-09 | Tier 4: intronic/intergenic | ||||||
| chr1:149946719 | 2e-09 | Tier 4: intronic/intergenic | ||||||
| chr10:98240797 | 3e-09 | Tier 4: intronic/intergenic | ||||||
| chr1:102766961 | 5e-09 | Tier 4: intronic/intergenic | ||||||
| chr1:22064084 | 1e-08 | Tier 4: intronic/intergenic | ||||||
| chr15:66742474 | 1e-08 | Tier 4: intronic/intergenic | ||||||
| chr10:119663324 | 2e-08 | Tier 4: intronic/intergenic | ||||||
| chr10:27589391 | 2e-08 | Tier 4: intronic/intergenic | ||||||
| chr5:83519339 | 2e-08 | Tier 4: intronic/intergenic | ||||||
| chr3:136157283 | 2e-08 | Tier 4: intronic/intergenic | ||||||
| chr10:21510797 | 3e-08 | Tier 4: intronic/intergenic | ||||||
| chr6:85086735 | 3e-08 | Tier 4: intronic/intergenic | ||||||
| chr7:44129973 | 3e-08 | Tier 4: intronic/intergenic | ||||||
| chr5:73343274 | 4e-08 | Tier 4: intronic/intergenic | ||||||
| chr1:68484837 | 5e-08 | Tier 4: intronic/intergenic |
Genes & proteins
No associated-gene cohort resolved for this disease. Atlas builds the molecular and therapeutic sections — associated genes, protein families, druggability, pathways, interactions, and drug associations — by aggregating over a disease’s associated genes (resolved via GWAS / GenCC / ClinVar / CIViC), and none resolved here. This is expected for antibody-mediated, autoimmune, or otherwise non-gene-defined conditions; the curated evidence for this disease is its clinical features, GWAS susceptibility, and clinical trials (above).
Function
No pathway enrichment — requires an associated-gene cohort.
Therapeutics
Drugs indicated for this disease
0 approved, 1 in late-stage (phase 3) trials. Disease-direct ChEMBL indications, not inferred from the associated-gene cohort below.
| Drug | Development status |
|---|---|
| Pregabalin | Phase 3 (in late-stage trials) |
Clinical trials & evidence
Clinical trials
Clinical trials: 4.
Phase distribution (across all retrieved trials)
| Phase | Trials |
|---|---|
| Not specified | 3 |
| PHASE2 | 1 |
Top trials by phase / activity
| NCT | Phase | Status | Title |
|---|---|---|---|
| NCT00964990 | PHASE2 | TERMINATED | A Study to Evaluate the Efficacy, Safety, and Tolerability of JNJ-42160443 in Patients With Neuropathic Pain (Postherpetic Neuralgia and Post-traumatic Neuralgia) |
| NCT06546371 | Not specified | RECRUITING | Spinal Cord Stimulation for Intractable Mononeuropathy |
| NCT07166302 | Not specified | RECRUITING | Ultrasound Evaluation of Hematoma Risk After Needle EMG in Patient on DOAC Therapy |
| NCT07515989 | Not specified | RECRUITING | Accuracy of the Polymerase Chain Reaction of Ulnar Perineural Subcutaneous Aspirate Guided by Ultrasound for the Diagnosis and Monitoring of Leprosy Cure |
Drugs tested across these trials (top 30)
| Molecule | Max phase | Trials referencing |
|---|---|---|
| FULRANUMAB | 3 | 1 |
Related Atlas pages
- Drugs: Fulranumab